The Center for Medical Technology Policy (CMTP) hosted a one day Think Tank on November 12, 2009 with more than 60 experts and stakeholders to reach consensus on better ways to more frequently and consistently design, fund, and implement prospective clinical studies of new indications for oncology drugs that will be more informative to post-regulatory decision makers. The Think Tank was not intended to find ways to extract knowledge from routinely collected information; rather, it was about designing prospective studies of existing oncology drugs used for new indications. The overarching goal of the Think Tank was to develop specific recommendations and principles to serve as a basis for a guidance document for the design of trials for new indications of cancer drugs. Please review the meeting summary for a full overview of the Think Tank, 
NI Meeting Summary (pdf) (392.94 kB)
The results of the Think Tank also led to an Effectiveness Guidance Document, “Designing New Indications of Approved Oncology Drugs.”